GlassScriptPhysician profile
Stephanie Moline
NPI 1225027436
$3,402.15
in general payments reported to CMS, 2019-2025
25 companies · $884 in 2025
The $884 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $51.31 · 2023: $22.45 · 2024: $2,444 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,325 · Travel and Lodging: $974 · Education: $51.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,325.31 |
| Travel and Lodging | $973.63 |
| Education | $51.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elucent Medical | $973.63 | 2024 | |
| Endomagnetics LTD | $507.82 | 2024 | Magtrace, Magseed |
| Astrazeneca Pharmaceuticals LP | $498.30 | 2024-2025 | Lynparza, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $211.27 | 2024-2025 | |
| Solventum Corporation | $195.87 | 2024-2025 | Prevena, Prevena Restor Bellaform, V.A.C.Ulta |
| Gilead Sciences, INC. | $143.23 | 2024 | Trodelvy |
| Kub Technologies INC. | $109.16 | 2024 | |
| Merck Sharp & Dohme LLC | $108.09 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pacira Pharmaceuticals Incorporated | $93.91 | 2024 | Exparel |
| Myriad Genetic Laboratories, INC. | $82.70 | 2022-2025 | Precisetumor |
| Dendreon Pharmaceuticals LLC | $65.49 | 2025 | Provenge |
| Incyte Corporation | $57.89 | 2024-2025 | Jakafi, Zynyz, Pemazyre |
| Lilly USA, LLC | $52.27 | 2025 | Verzenio |
| Janssen Biotech, INC. | $51.92 | 2025 | Erleada, Balversa, Akeega |
| Abbvie INC. | $33.64 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $32.17 | 2024 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $29.83 | 2024 | Iclusig |
| Pharmacosmos Therapeutics INC. | $27.82 | 2025 | Monoferric |
| Pharmaand Gmbh | $21.75 | 2025 | Rubraca |
| Eisai INC. | $19.55 | 2025 | |
| Agios Pharmaceuticals, INC. | $19.36 | 2025 | Pyrukynd |
| Adc Therapeutics America, INC. | $19.11 | 2024 | |
| Daiichi Sankyo INC. | $17.05 | 2024 | Injectafer |
| Genentech USA, INC. | $16.58 | 2025 | Itovebi |
| Blueprint Medicines Corporation | $13.74 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Moline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.